Firmonertinib
Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].
Product Specifications
CAS Number
1869057-83-9
Product Name Alternative
Alflutinib; Furmonertinib; AST2818
UNSPSC
12352005
Hazard Statement
H315, H319
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/firmonertinib.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O
Molecular Formula
C28H31F3N8O2
Molecular Weight
568.59
Precautions
H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Von Willebrand Factor (3E2D10), CF555 conjugate, 0.1mg/mL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF568 conjugate, 0.1mg/mL
